CAT 2003

Drug Profile

CAT 2003

Alternative Names: CAT-2003; Niacin-eicosapentaenoic acid conjugate

Latest Information Update: 24 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Catabasis Pharmaceuticals
  • Class Antihyperlipidaemics; Eicosanoids; Lipids; Nicotinic-acids; Omega 3 fatty acids; Peripheral vasodilators; Small molecules; Vitamins
  • Mechanism of Action Sterol regulatory element binding protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Non-alcoholic steatohepatitis
  • No development reported Hypercholesterolaemia; Hyperlipoproteinaemia type I; Hypertriglyceridaemia

Most Recent Events

  • 24 May 2016 No development reported - Phase-II for Hypercholesterolaemia (Adjunctive treatment) in USA, Canada (PO)
  • 24 May 2016 No development reported - Phase-II for Hyperlipoproteinaemia type I in Canada (PO)
  • 24 May 2016 No development reported - Phase-II for Hypertriglyceridaemia in Canada, USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top